Rashad Falah: Evaluating Long Term Outcomes and Transfusion Risks in Obscure Gastrointestinal Bleeding
Rashad Falah, Medical Doctor at Rambam Health Care Campus, shared a post on LinkedIn about a recent article he and his colleague co-authored, published in BMC Gastroenterology, adding:
“In our new publication in BMC Gastroenterology (as an equally contributing author), we evaluated long term hematologic outcomes following double balloon enteroscopy (DBE) in patients with obscure gastrointestinal bleeding.
Our study showed that while hemoglobin levels improved overall after DBE, patients requiring therapeutic intervention represented a higher risk subgroup with more severe baseline anemia and persistent transfusion needs despite endoscopic therapy.
These findings support the need for combined endoscopic and adjunctive medical therapy in complex small bowel bleeding.”
Title: Clinical outcomes after deep enteroscopy in patients with obscure gastrointestinal bleeding: a single-center retrospective study
Authors: Nour Ershaid, Rashad Falah, Amir Klein, Itay Maza

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
-
Aug 31, 2026, 14:23Accelerating CAR-T Access Through Policy and System Reform – American Society of Hematology
-
Aug 31, 2026, 14:21Shirya Rashid: Does Bempedoic Acid Influence Venous Thromboembolism Risk?
-
Aug 31, 2026, 14:14Jason Andrade: SINGLE-AF Trial Validates Early Anticoagulation in AF
-
Aug 31, 2026, 14:12Leonardo Roever: Diagnosis and Management of Natural Anticoagulant Deficiencies
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery